A Phase 1 interventional study of Brexpiprazole and Placebo in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 4 sites in United States. Open to participants aged 70 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-02-04.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 21st largest by enrollment, is one of 2 that started in 2012, is the only one in phase 1, and was the 6th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 70 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 17 · Phase 4 3
First in 2009; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 189 across the 24 interventional studies. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 37th largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2012, is one of 3 in phase 1, and was the 22nd registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and tolerability of ascending multiple oral doses of brexpiprazole as adjunctive therapy in the treatment of elderly subjects with MDD.
This is a phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose trial in 3 sequential cohorts of elderly subjects (age 70 to 85 years old) with MDD. Brexpiprazole will be administered as an adjunct treatment to the current antidepressant therapy that the subject is receiving. Total individual subject duration is expected to be no more than 119 days (a 30-day screening period, a 14-day washout period, up to 45-day in-clinic treatment period, and a 30-day follow-up after the last dose of trial medication).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with a current Axis I () diagnosis of:
The following laboratory test and results are exclusionary:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
14 day titration phase and two fixed dose phases. The first fixed dose phase is 14 days with a daily dose of 2mg brexpiprazole/placebo. The second fixed dose phase is 14 days with a daily dose of 3 mg brexpiprazole/placebo.
Drug: Brexpiprazole
14 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
Drug: Brexpiprazole
21 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
Drug: Brexpiprazole
Placebo
Drug: Placebo
up to 3mg oral dose once daily
Number of Participants Who Tolerated Brexpiprazole
Safety and tolerability of brexpiprazole was noted to be primary outcome measure. Brexpiprazole was judged to be tolerated if at least 6 out of 8 (75%) of the participants in a test cohort tolerated the dose after 14 days of QD dosing at the end of the fixed dose phase based on the blinded data. Dose toleration was defined as follows: during the course of the trial, the participants did not experience any moderate or severe adverse events (AEs) or potentially clinically relevant changes from Baseline in laboratory values, vital signs, electrocardiogram (ECG) tracings, Columbia-Suicide Severity Rating Scale (C-SSRS), or extrapyramidal symptom (EPS) ratings, which were assessed as possibly related to the study drug, and would have warranted a dose decrease or discontinuation of the study drug. The safety and tolerability of brexpiprazole was defined by parameters: AEs, laboratory values, vital signs, ECG, C-SSRS, or EPS ratings, the results of each of the parameters reported separately.
Time frame: 45 Days
Number of AEs Reported.
The AEs were one of the primary parameters to measure the safety and tolerability of individual participants. The AEs were captured for all participants from the time the ICF was signed until the end of the trial. AEs were measured throughout the 14-day titration and 28-day fixed dose phase until follow-up (30 \[±2\] days after last dose of study medication).
Time frame: Throughout the study, up to 119 days
Incidence of Laboratory Values of Potential Clinical Significance
The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria.
Time frame: Titration Day 7, Fixed dose Day 14 and 28 and Last Visit
Incidence of Vital Signs of Potential Clinical Significance
The vital signs were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria.
Time frame: Baseline, Titration Day 1, 2, 7, 8, Fixed Days 1, 2, 14, 15, 28, 29, Early Termination and Last Visit.
Incidence of ECG Evaluations of Potential Clinical Significance
The measurement of ECG was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, and QTcF that were identified based on pre-defined criteria.
Time frame: Titratrion Day 1 and 7, Fixed dose Day 1, 14, 28, Early Termination
Incidence of Physical Examination Evaluation of Potential Clinical Significance
The physical examination evaluation was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.
Time frame: Physical examination was performed at Screening, check-in, and discharge
Mean Change From Baseline to Study Completion in Simpson-Angus Scale (SAS) Total Score
EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40.
Time frame: End of Titration, Day 15, Day 29, Early Termination and Last visit
Mean Change From Baseline to Study Completion in Barnes Akathisia Global Score
EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The Barnes Akathisia Rating Scale was an EPS rating scale. The Barnes Akathisia Rating Scale was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia).
Time frame: End of Titration, Day 15, Day 29, Early Termination and Last visit
Mean Change From Baseline to Study Completion in Abnormal Involuntary Movement Scale (AIMS) Rating Score.
EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The AIMS Scale was an EPS rating scale. The AIMS is a 12 item scale. The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28.
Time frame: End of Titration, Day 15, Day 29, Early Termination and Last visit
Change From Baseline to Study Completion in C-SSRS Score.
The C-SSRS was one of the primary parameters to measure the safety and tolerability of individual participants. Suicidality was monitored during the trial using the C-SSRS. This scale consists of a baseline evaluation that assesses the lifetime experience of the participant with suicide events and suicidal ideation and a post-baseline evaluation that focuses on suicidality since the last trial visit.
Time frame: Baseline, End of Titration, Fixed dose Day 14 and 28, Day 15 and 29, Early Termination, Last Visit
This was a phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose trial planned in 3 sequential cohorts of elderly participants (70 to 85 years old) with major depressive disorder (MDD). Brexpiprazole was administered as an adjunct treatment to the current antidepressant therapy that the participant received.
| Milestone | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Brexpiprazole-Cohort 3 | Placebo |
|---|---|---|---|---|
| Started | 6 | 7 | 0 | 5 |
| Completed | 6 | 5 | 0 | 4 |
| Not completed | 0 | 2 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Participant met withdrawal criteria | 0 | 0 | 0 | 1 |
Safety and tolerability of brexpiprazole was noted to be primary outcome measure. Brexpiprazole was judged to be tolerated if at least 6 out of 8 (75%) of the participants in a test cohort tolerated the dose after 14 days of QD dosing at the end of the fixed dose phase based on the blinded data. Dose toleration was defined as follows: during the course of the trial, the participants did not experience any moderate or severe adverse events (AEs) or potentially clinically relevant changes from Baseline in laboratory values, vital signs, electrocardiogram (ECG) tracings, Columbia-Suicide Severity Rating Scale (C-SSRS), or extrapyramidal symptom (EPS) ratings, which were assessed as possibly related to the study drug, and would have warranted a dose decrease or discontinuation of the study drug. The safety and tolerability of brexpiprazole was defined by parameters: AEs, laboratory values, vital signs, ECG, C-SSRS, or EPS ratings, the results of each of the parameters reported separately.
| participants | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Placebo |
|---|---|---|---|
| Number of Participants Who Tolerated Brexpiprazole | 6 | 7 | 5 |
The AEs were one of the primary parameters to measure the safety and tolerability of individual participants. The AEs were captured for all participants from the time the ICF was signed until the end of the trial. AEs were measured throughout the 14-day titration and 28-day fixed dose phase until follow-up (30 \[±2\] days after last dose of study medication).
| Events | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Placebo |
|---|---|---|---|
| Adverse events | 12 | 33 | 5 |
| Treatment emergent adverse events (TEAEs) | 6 | 6 | 3 |
| Serious adverse events | 0 | 0 | 0 |
The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria.
| Participants | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Placebo |
|---|---|---|---|
| Cholesterol, fasting | 0 | 1 | 1 |
| Glucose | 0 | 0 | 1 |
| LDL direct, fasting | 0 | 0 | 1 |
| Triglycerides, fasting | 2 | 1 | 3 |
| Uric acid | 0 | 0 | 1 |
| Hematocrit | 0 | 2 | 1 |
| Prolactin | 2 | 0 | 0 |
The vital signs were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria.
| Participants | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Placebo |
|---|---|---|---|
| Weight increase | 2 | 0 | 0 |
| Supine hypotension, decrease | 1 | 0 | 0 |
The measurement of ECG was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, and QTcF that were identified based on pre-defined criteria.
| Participants | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Placebo |
|---|---|---|---|
| Supraventricular premature beat | 0 | 2 | 1 |
| Ventricular premature beat | 3 | 0 | 1 |
| Left bundle-branch block | 0 | 0 | 1 |
| Myocardial ischemia | 1 | 0 | 0 |
| Symmetrical T-wave inversions | 1 | 1 | 0 |
| Increase in QTcB | 1 | 3 | 2 |
| Increase in QTcF | 1 | 2 | 2 |
The physical examination evaluation was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.
| Participants | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Placebo |
|---|---|---|---|
| Incidence of Physical Examination Evaluation of Potential Clinical Significance | 0 | 0 | 0 |
EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40.
| Units on a scale | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Placebo |
|---|---|---|---|
| End of Titration (N= 6, 6, 4) | -0.3 ± 0.5 | -0.5 ± 0.8 | -1.0 ± 0.8 |
| Day 15 (N= 0, 5, 2) | NA ± NA | 0.2 ± 0.4 | -1.5 ± 0.7 |
| Day 29 (N=6, 0, 2) | -0.3 ± 0.4 | NA ± NA | 0.0 ± 0.0 |
| Early Termination (N= 0, 1, 1) | NA ± NA | -1.0 ± NA | 0.0 ± NA |
| Last visit (N= 6, 6, 5) | -0.2 ± 0.4 | 0.0 ± 0.6 | -0.6 ± 0.9 |
EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The Barnes Akathisia Rating Scale was an EPS rating scale. The Barnes Akathisia Rating Scale was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia).
| Units on a scale | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Placebo |
|---|---|---|---|
| End of Titration (N= 6, 6, 4) | -0.2 ± 0.4 | 0.0 ± 0.0 | -0.5 ± 0.6 |
| Day 15 (N= 0, 5, 2) | NA ± NA | 0.0 ± 0.0 | -0.5 ± 0.7 |
| Day 29 (N= 6, 0, 2) | 0.0 ± 0.0 | NA ± NA | -0.5 ± 0.7 |
| Early Termination (N= 0, 1, 1) | NA ± NA | 0.0 ± NA | 0.0 ± NA |
| Last visit (N= 6, 6, 5) | 0.0 ± 0.0 | 0.0 ± 0.0 | -0.4 ± 0.5 |
EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The AIMS Scale was an EPS rating scale. The AIMS is a 12 item scale. The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28.
| Units on a scale | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Placebo |
|---|---|---|---|
| End of Titration (N= 6, 6, 4) | 0.0 ± 0.0 | 0.2 ± 0.4 | 0.0 ± 0.0 |
| Day 15 (N= 0, 5, 2) | NA ± NA | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Day 29 (N= 6, 0, 2) | 0.0 ± 0.0 | NA ± NA | 0.0 ± 0.0 |
| Early Termination (N= 0, 1, 1) | NA ± NA | 0.0 ± NA | 0.0 ± NA |
| Last Visit (N= 6, 6, 5) | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
The C-SSRS was one of the primary parameters to measure the safety and tolerability of individual participants. Suicidality was monitored during the trial using the C-SSRS. This scale consists of a baseline evaluation that assesses the lifetime experience of the participant with suicide events and suicidal ideation and a post-baseline evaluation that focuses on suicidality since the last trial visit.
| Participants | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Placebo |
|---|---|---|---|
| Suicidality | 0 | 0 | 0 |
| Suicidal behaviour | 0 | 0 | 0 |
| Suicidal ideation | 0 | 0 | 0 |
Collected over AEs were captured for all participants from the signing of the informed consent and were measured throughout the 14-day titration period, 28-day fixed dose period until follow-up (30 [±2] days after last dose of study medication).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole-Cohort 1 | — | 0/6 (0%) | 6/6 (100%) |
| Brexpiprazole-Cohort 2 | — | 0/6 (0%) | 6/6 (100%) |
| Placebo | — | 0/5 (0%) | 1/5 (20%) |
| Event | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Placebo |
|---|---|---|---|
| DizzinessNervous system disorders | 0/6 | 3/6 | 0/5 |
| DyspepsiaGastrointestinal disorders | 0/6 | 2/6 | 0/5 |
| NauseaGastrointestinal disorders | 0/6 | 2/6 | 0/5 |
| Weight increasedInvestigations | 2/6 | 0/6 | 0/5 |
| PollakiuriaRenal and urinary disorders | 2/6 | 0/6 | 0/5 |
| HeadacheNervous system disorders | 1/6 | 0/6 | 1/5 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/6 | 0/6 | 1/5 |
| Eye pruritisEye disorders | 0/6 | 0/6 | 1/5 |
| Dry eyeEye disorders | 0/6 | 0/6 | 1/5 |
| Atrioventricular block first degreeCardiac disorders | 1/6 | 1/6 | 0/5 |
| Age, Continuous(Years) | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Placebo | Total |
|---|---|---|---|---|
| Mean | 73.2 ± 4.0 | 76.0 ± 5.3 | 72.6 ± 1.5 | 74.1 ± 4.2 |
| Sex: Female, Male(Participants) | Brexpiprazole-Cohort 1 | Brexpiprazole-Cohort 2 | Placebo | Total |
|---|---|---|---|---|
| Female | 4 | 5 | 4 | 13 |
| Male | 2 | 2 | 1 | 5 |
The record gives a start of Jul 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →